avinger, inc. is a commercial-stage medical device company that designs, manufactures and sells image-guided, catheter-based systems for the treatment of patients with peripheral artery disease (pad). pad is characterized by a build-up of plaque in the arteries that supply blood to the arms and legs. the company’s mission is to radically change the way vascular disease is treated through the introduction of products based on its lumivascular platform, the only intravascular image-guided system of therapeutic catheters available in this market. avinger’s current lumivascular products include the lightbox imaging console, the ocelot family of catheters, which are designed to penetrate total arterial blockages, known as chronic total occlusions, or ctos, and pantheris, the first-ever image- guided atherectomy device, designed to precisely remove arterial plaque in pad patients.
Company profile
Ticker
AVGR
Exchange
Website
CEO
Jeffrey Soinski
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
AVGR stock data
Latest filings (excl ownership)
8-K
Avinger Announces Pricing of up to $24 Million Public Offering
17 Jun 24
424B4
Prospectus supplement with pricing info
14 Jun 24
EFFECT
Notice of effectiveness
14 Jun 24
S-1/A
IPO registration (amended)
11 Jun 24
S-1/A
IPO registration (amended)
7 Jun 24
8-K
Entry into a Material Definitive Agreement
7 Jun 24
SD
Conflict minerals disclosure
31 May 24
8-K
Other Events
31 May 24
8-K
Submission of Matters to a Vote of Security Holders
28 May 24
S-1
IPO registration
24 May 24
Transcripts
AVGR
Earnings call transcript
2024 Q1
15 May 24
AVGR
Earnings call transcript
2023 Q4
20 Mar 24
AVGR
Earnings call transcript
2023 Q3
26 Oct 23
AVGR
Earnings call transcript
2023 Q2
27 Jul 23
AVGR
Earnings call transcript
2023 Q2
27 Jul 23
AVGR
Earnings call transcript
2023 Q1
10 May 23
AVGR
Earnings call transcript
2022 Q4
15 Mar 23
AVGR
Earnings call transcript
2022 Q3
13 Nov 22
AVGR
Earnings call transcript
2022 Q3
9 Nov 22
AVGR
Earnings call transcript
2022 Q2
12 Aug 22
Latest ownership filings
SC 13G/A
CR Group L.P.
15 Mar 24
3
Jonathon Zhong Zhao
14 Mar 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Himanshu Patel
22 Jan 24
4
JEFFREY M SOINSKI
22 Jan 24
4
JAMES CULLEN
17 Jan 24
4
Tamara Elias
17 Jan 24
4
JAMES B MCELWEE
17 Jan 24
SC 13G/A
CR Group L.P.
14 Aug 23
4
Change in insider ownership
9 Aug 23
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.17 mm | 7.17 mm | 7.17 mm | 7.17 mm | 7.17 mm | 7.17 mm |
Cash burn (monthly) | (no burn) | 266.33 k | 1.70 mm | 1.46 mm | 1.58 mm | 1.25 mm |
Cash used (since last report) | n/a | 702.90 k | 4.48 mm | 3.84 mm | 4.16 mm | 3.29 mm |
Cash remaining | n/a | 6.47 mm | 2.70 mm | 3.33 mm | 3.01 mm | 3.89 mm |
Runway (months of cash) | n/a | 24.3 | 1.6 | 2.3 | 1.9 | 3.1 |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 1 |
Closed positions | 11 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 2.27 mm |
Total shares | 2.78 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CR | 2.68 mm | $1.88 mm |
CVI Investments | 100.00 k | $44.00 k |
City State Bank | 225.00 | $1.00 k |
HighMark Wealth Management | 127.00 | $344.00 k |
Householder Group Estate & Retirement Specialist | 1.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Jan 24 | Himanshu Patel | Common Stock | Payment of exercise | Dispose F | No | No | 2.725 | 24,616 | 67.08 k | 41,277 |
18 Jan 24 | Himanshu Patel | Common Stock | Grant | Acquire A | No | No | 0 | 55,553 | 0.00 | 65,893 |
18 Jan 24 | Jeffrey M Soinski | Common Stock | Payment of exercise | Dispose F | No | No | 2.725 | 32,254 | 87.89 k | 58,955 |
18 Jan 24 | Jeffrey M Soinski | Common Stock | Grant | Acquire A | No | No | 0 | 74,071 | 0.00 | 91,209 |
11 Jan 24 | Tamara Elias | Common Stock | Grant | Acquire A | No | No | 0 | 25,597 | 0.00 | 29,962 |
11 Jan 24 | James B Mcelwee | Common Stock | Grant | Acquire A | No | No | 0 | 25,597 | 0.00 | 29,895 |
News
Why Streamline Health Solutions Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
12 Jun 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Jun 24
Avinger Converts $11M Of CRG Debt Into Preferred Equity
16 May 24
Avinger Q1 2024 GAAP EPS $(2.49) Misses $(1.35) Estimate, Sales $1.859M Miss $2.360M Estimate
15 May 24
Press releases
Avinger Announces Closing of up to $24 Million Public Offering
17 Jun 24
Avinger Announces Pricing of up to $24 Million Public Offering
14 Jun 24
Avinger Increases Focus on Coronary Development, Reduces Operating Costs of Peripheral Business
5 Jun 24
Avinger Announces Conversion of $11 Million of CRG Debt into Preferred Equity
16 May 24
Avinger to Announce First Quarter 2024 Results on May 15, 2024
7 May 24